IL23A and inflammatory bowel disease: Using bispecific antibodies (BsAbs) to target TNF‐α and IL‐23p19 simultaneously has emerged as a promising strategy to improve therapeutic efficacy and simplify combinatorial therapy for IBD.21, 22